Chronic Sigma 1 receptor activation alleviates right ventricular dysfunction secondary to pulmonary arterial hypertension
Authors:
Open Access
- 27 April 2022
- journal article
- research article
- Published by Taylor & Francis in Bioengineered
- Vol. 13 (4) , 10843-10856
Abstract
Sigma 1 receptor (S1R) has shown a preferable protective effect on left ventricular function, but whether it protects right ventricular (RV) function is still elusive.This study aimed to determine the effects of S1R on RV dysfunction secondary to pulmonary arterial hypertension.Sixty wild-type male Sprague–Dawley rats were randomly divided into the control group, the fluvoxamine group, the pulmonary arterial hypertension group and the pulmonary arterial hypertension combined with fluvoxamine group. Monocrotaline (60 mg/kg) was administered to induce pulmonary arterial hypertension, and fluvoxamine was given for 21 consecutive days to activate S1R after one week of monocrotaline administration. Echocardiographic, serologic, and histologic parameters, qRT-PCR, and western blotting were conducted after 4 weeks of monocrotaline administration.The expression of S1R was decreased in the right ventricle in pulmonary arterial hypertension. TAPSE, and the FAC of the right ventricle were significantly decreased, and RV EDP and the plasma concentration of N-terminal pro-B-type natriuretic peptide was increased in the pulmonary arterial hypertension group, but fluvoxamine partly restored those abnormalities (all P < 0.05). Moreover, pulmonary arteriole remodeling, and fibrosis and hypertrophy in the RV were shown in the pulmonary arterial hypertension group; interestingly, fluvoxamine recovered RV structural remodeling (all P < 0.05) but neither alleviated pulmonary arteriole remodeling nor reduced pulmonary artery pressure. Furthermore, S1R activation protects RV function by upgrading the NRF 2/HO 1-mediated antioxidant stress pathway. In conclusion, chronic S1R activation ameliorates structural remodeling and RV dysfunction secondary to pulmonary arterial hypertension without altering pulmonary artery pressure.Keywords
Funding Information
- National Natural Science Foundation of China (81800447, No. 81500278)
- Natural Science Foundation of Hubei Province (2017CFB204)
This publication has 45 references indexed in Scilit:
- Pulmonary Artery Denervation to Treat Pulmonary Arterial HypertensionJACC, 2013
- Toward clinical application of the Keap1–Nrf2 pathwayTrends in Pharmacological Sciences, 2013
- The sigma-1 receptor protects against cellular oxidative stress and activates antioxidant response elementsEuropean Journal of Pharmacology, 2012
- Decreased brain sigma-1 receptor contributes to the relationship between heart failure and depressionCardiovascular Research, 2011
- Exacerbated Pulmonary Arterial Hypertension and Right Ventricular Hypertrophy in Animals With Loss of Function of Extracellular Superoxide DismutaseHypertension, 2011
- Sigma Receptor 1 Modulates Endoplasmic Reticulum Stress in Retinal NeuronsInvestigative Ophthalmology & Visual Science, 2011
- σ1-Receptor stimulation with fluvoxamine ameliorates transverse aortic constriction-induced myocardial hypertrophy and dysfunction in miceAmerican Journal of Physiology-Heart and Circulatory Physiology, 2010
- Targeting sigma-1 receptor with fluvoxamine ameliorates pressure-overload-induced hypertrophy and dysfunctionsExpert Opinion on Therapeutic Targets, 2010
- The pharmacology of sigma-1 receptorsPharmacology & Therapeutics, 2009
- Oxidative Stress in Severe Pulmonary HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2004